

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

CLARIFICATION ANNOUNCEMENT

The board (the “**Board**”) of directors of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) wishes to clarify that as at the date of this announcement, none of the Company and its subsidiaries has been included in the “Unverified List” (the “**UVL**”) on February 8, 2022 (U.S. time) as announced by the U.S. Department of Commerce.

The Board noted that two subsidiaries of WuXi Biologics (Cayman) Inc. are among the entities which are being included in the UVL. WuXi Biologics (Cayman) Inc. is a separate entity listed on the Main Board of The Stock Exchange of Hong Kong Limited (Stock Code: 2269) in which the Company has no shareholding interest.

The Board also wishes to confirm that the business and operations of the Company remain normal.

Investors should exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, February 8, 2022

As at the date of this announcement, the Board comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* For identification purposes only